Palynziq
PreclinicalSmall molecule
Palynziq is one of 17 small molecule programs targeting Phenylketonuria. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Phenylketonuria
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
L-Carnitine
IIperboreal Pharma Srl
Approved
BMN 333
BioMarin PharmaceuticalPhase 2
CEB-01
BioMarin PharmaceuticalPhase 3
PTC923
PPTC Therapeutics
Phase 3
Kuvan
BioMarin PharmaceuticalPreclinical
Immunosuppression
NNational Heart, Lung, and Blood Institute (NHLBI)
Phase 2
Kuvan
BioMarin PharmaceuticalPreclinical
Tetrahydrobiopterin
OOrphanetics Pharma Entwicklungs GmbH
Phase 1
Kuvan
BioMarin PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Palynziq. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- EEmory University